Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function
Diabetes, Obesity and Metabolism · 2023-09 · 25 (9) · 2473-2481
DOI: 10.1111/dom.15073 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.06.2023. Verfasst von Ravi Retnakaran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CIHR, Banting and Best Diabetes Centre, University of Toronto, Canadian Institutes of Health Research.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To identify baseline determinants of diabetes remission in response to short‐term insulin‐based therapy.
Methods
In this study, adult patients with type 2 diabetes (T2D) of less than 7 years duration were randomized to 8 weeks of treatment with (a) insulin glargine, (b) glargine + thrice‐daily lispro, or (c) glargine + twice‐daily exenatide, followed by 12 weeks of washout that enabled assessment of remission (defined as HbA1c < 6.5% after ≥ 3 months without glucose‐lowering therapy). At baseline, 8 weeks and washout, beta‐cell function was assessed with four measures: Insulin Secretion‐Sensitivity Index‐2 (ISSI‐2), insulinogenic index/Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR), ΔC‐peptide 0‐120 /Δglucose 0‐120 × Matsuda and Δinsulin secretion rate (ISR) 0‐120 /Δgluc 0‐120 × Matsuda.
Results
Diabetes remission was achieved in 31 of 90 participants (34.4%). Compared with their peers, those who went on to remission had lower HbA1c ( P < .001) and better beta‐cell function at baseline (all four measures P ≤ .01). The non‐remission and remission groups did not otherwise differ in baseline insulin sensitivity/resistance (Matsuda, HOMA‐IR), body mass index, duration of diabetes, pretrial diabetes medications or allocated insulin‐based therapy during the trial. On logistic regression analyses, each baseline measure of beta‐cell function emerged as a significant predictor of remission (log ISSI‐2: adjusted OR 4.41 [95% CI: 1.71‐11.34]; log insulinogenic index/HOMA‐IR: 2.21 [1.26‐3.89]; log ΔC‐peptide 0‐120 /Δglucose 0‐120 × Matsuda: 1.62 [1.00‐2.64]; log ΔISR 0‐120 /Δgluc 0‐120 × Matsuda: 1.87 [1.09‐3.23]). Similarly, higher baseline ISSI‐2 tertile predicted longer time to glycaemic relapse after cessation of the insulin‐based therapy (log‐rank P = .029).
Conclusion
Beta‐cell function is the dominant baseline pathophysiological determinant of the likelihood of achieving remission of diabetes in response to short‐term insulin‐based therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Ravi Retnakaran, Bernard Zinman
Förderung
- CIHR
- Banting and Best Diabetes Centre, University of Toronto
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Canada
Zitieren
APA
Retnakaran, R., Pu, J., Emery, A., Kramer, C. K., & Zinman, B. (2023). Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function. Diabetes, Obesity and Metabolism, 25(9), 2473-2481. https://doi.org/10.1111/dom.15073
Vancouver
Retnakaran R, Pu J, Emery A, Kramer CK, Zinman B. Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function. Diabetes, Obesity and Metabolism. 2023;25(9):2473-2481. doi:10.1111/dom.15073
BibTeX
@article{Retnakaran2023,
author = {Retnakaran, Ravi and Pu, Jiajie and Emery, Alexandra and Kramer, Caroline K and Zinman, Bernard},
title = {Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {9},
pages = {2473--2481},
doi = {10.1111/dom.15073}
}
EUVIMED